Company Overview
RedHill Biopharma Ltd. operates as a specialty biopharmaceutical entity dedicated to the development and commercialization of therapeutic solutions primarily for gastrointestinal and infectious diseases. The company's core portfolio includes Talicia, which targets H. pylori infection in adults, and Aemcolo, designed for the treatment of travelers' diarrhea in adults. This business model places RedHill within the Healthcare sector, specifically under the industry classification of Drug Manufacturers - Specialty & Generic, distinguishing it from mass-market pharmaceutical producers by its focus on niche therapeutic areas. The organization maintains a lean operational footprint with a workforce of 35 employees, generating a trailing twelve-month revenue of $9.55M while maintaining a total market capitalization of $3.83M. These valuation and revenue figures indicate that the company is a small-cap entity with a relatively limited market presence compared to large-cap peers, operating with a capital structure that reflects early-stage growth characteristics rather than mature industry dominance.
Financial Health
The company reported a revenue of $9.55M for the trailing twelve months, yet posted a net income of $-9,313,000 and an EBITDA of $-8,336,000, revealing a significant gap between top-line generation and profitability. This disparity highlights a cost structure where operating expenses and research and development expenditures substantially exceed current revenue streams, a typical dynamic for biopharmaceutical firms in the development or commercialization phases. Free cash flow stands at $-4,080,000, indicating that the company is burning through cash reserves to fund its operations and pipeline advancement rather than generating surplus liquidity for immediate reinvestment or shareholder returns. The gross margin is reported at 64.4%, suggesting favorable pricing power or low cost of goods sold for its finished products, while the operating margin of -107.3% and profit margin of -97.5% underscore the heavy overhead costs associated with maintaining a specialty drug pipeline. Liquidity is supported by $2.87M in cash against a debt obligation of only $214,000, although the debt-to-equity ratio is listed as N/A due to the company's negative equity position. The current ratio of 0.56 suggests that the company's current assets do not fully cover its current liabilities, signaling potential short-term liquidity constraints that require careful management of cash burn rates. Return on Equity and Return on Assets are both listed as N/A or negative, with the Return on Assets specifically showing -25.3%, which indicates that the company's assets are currently generating a net loss rather than contributing to shareholder value.
Valuation Assessment
Valuation metrics present a mixed picture, with the P/E Ratio (TTM) listed as N/A due to losses, while the Forward P/E is calculated at 25.00, implying market expectations for future profitability that differ significantly from current earnings performance. The price-to-book ratio is -0.31, a negative figure that indicates the market values the company at less than its net book value, often reflecting high uncertainty regarding the recoverability of assets or the value of the intangible drug pipeline. The price-to-sales ratio sits at 0.40, suggesting the market values the company at 40% of its revenue, a metric that can be relevant for unprofitable growth companies where sales growth is the primary valuation driver. Additionally, the EV/EBITDA stands at -1621.86, a metric that is distorted by the company's negative earnings and suggests that traditional multiple-based comparisons with profitable peers are not applicable at this stage. Price action over the last year shows a 52-week high of $3.31 and a 52-week low of $0.75, with the current share price trading in a range that reflects significant volatility and sensitivity to biotech sector sentiment. The stock exhibits a beta of 4.99, indicating that the security is nearly five times more volatile than the broader market, meaning price movements will be amplified relative to general market swings.
Growth & Income
Revenue growth for the trailing twelve months is recorded at 58.6%, demonstrating a rapid expansion in sales volume or market penetration, while earnings growth is listed as N/A due to the company's continued net losses. The disconnect between robust revenue growth and absent earnings growth implies that the company is reinvesting a large portion of its top-line gains into operational scaling or R&D rather than converting them into immediate profit. The company does not pay a dividend, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning all available cash flow is directed back into the business to support drug development and commercialization efforts rather than being distributed to shareholders. Consequently, the overall growth and income profile is characterized by high revenue expansion coupled with a complete reinvestment strategy, prioritizing long-term pipeline potential over current income generation or shareholder yield.